Large granular lymphocyte leukemia.
Clonal diseases of large granular lymphocytes (LGLs) represent a spectrum of clinically rare lymphoproliferative malignancies arising from either mature T-cell (CD3(+)) or natural killer (NK)-cell (CD3(-)) lineages. The clinical behavior of these disorders ranges from indolent to very aggressive. Patients with symptomatic indolent T-cell or NK-cell LGL leukemia are usually treated with immunosuppressive therapies; in contrast, aggressive T-cell or NK-cell LGL leukemias require intensive chemotherapy regimens. Novel targeted therapies are currently being tested in clinical studies.
Sokol
Lubomir
L
Penn State Cancer Institute, Penn State College of Medicine,500 University Drive, H072, Hershey, PA 17033, USA.
Loughran
Thomas P
TP
D000293:Adolescent; D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000473:pathology; D054066:Leukemia, Large Granular Lymphocytic / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D015458:Leukemia, T-Cell / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000473:pathology; D009503:Neutropenia / Q000209:etiology; D009894:Opportunistic Infections / Q000209:etiology; D033581:Stem Cell Transplantation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab